ArticlePharmaceuticals (Basel, Switzerland)2022
Wound-Healing Potential of Rhoifolin-Rich Fraction Isolated from
Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- New patchoulol- and guaiane-type sesquiterpenoids from Sanguisorba officinalis with anti-melanogenic activity.Natural products and bioprospecting · 2026Article
- Antimicrobial photodynamic therapy withFrontiers in cellular and infection microbiology · 2026Article
- SIRT1 mediated autophagy enhancement by Lactobacillus fermentum derived oligosaccharides accelerates wound healing in biofilm associated infection.Scientific reports · 2025Article
- Metabolic identification of bioactive compounds of Citrus reticulata cultivars extracts for a novel approach to polycystic ovary syndrome.Scientific reports · 2025Article
- Rhoifolin as a potential anxiolytic drug for the effects of nicotine withdrawal: beneficial effects on behavior, neuroinflammation, and oxidative stress.Metabolic brain disease · 2025Article
- Unveiling the potential antibacterial action of acetylcysteine for managing Staphylococcus aureus wound infections: in vitro and in vivo study.World journal of microbiology & biotechnology · 2025Article
- Antibacterial activity ofFrontiers in plant science · 2025Article
- Rhoifolin: A promising flavonoid with potent cytotoxic and anticancer properties: molecular mechanisms and therapeutic potential.EXCLI journal · 2025Review
- Phytochemical profiling ofRSC advances · 2024Article
- Bioactive Compounds inCurrent pharmaceutical design · 2024Review
- Plausible Protective Role ofPharmaceuticals (Basel, Switzerland) · 2023Article
- Celecoxib-Loaded Cubosomal Nanoparticles as a Therapeutic Approach forMicroorganisms · 2023Article
- The wound healing effect of botanicals and pure natural substances used in in vivo models.Inflammopharmacology · 2023Review
- In Vitro Antiviral Effect and Potential Neuroprotection ofPharmaceuticals (Basel, Switzerland) · 2023Article
- Fabrication of Celecoxib PVP Microparticles Stabilized by Gelucire 48/16 via Electrospraying for Enhanced Anti-Inflammatory Action.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Aqueous core epigallocatechin gallate PLGA nanocapsules: characterization, antibacterial activity against uropathogens, andDrug delivery · 2022Article
- Anti-Quorum Sensing and Anti-Biofilm Activity ofMolecules (Basel, Switzerland) · 2022Article
- Insight into Fucoidan-Based PEGylated PLGA Nanoparticles Encapsulating Methyl Anthranilic Acid: In Vitro Evaluation and In Vivo Anti-Inflammatory Study.Marine drugs · 2022Article
- Bilosomes as Nanoplatform for Oral Delivery and Modulated In Vivo Antimicrobial Activity of Lycopene.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Anti-Biofilm and Antibacterial Activities ofAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
A wound is a complicated bioprocess resulting in significant tissue damage, which is worsened by a secondary bacterial infection, commonly
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.